Pre Exposure Prophylaxis News and Research

RSS

Patients with high HIV risk are aware of preventative pill, but few are using it

Cisgender sexual minority men and transgender women are aware of pre-exposure prophylaxis (PrEP), a daily pill for HIV-negative people to prevent HIV infection, but few are currently taking it, according to researchers at Rutgers.

22 Apr 2021

Syphilis cases in California drive a record-setting year for STDs nationwide

In certain circles of San Francisco, a case of syphilis can be as common and casual as the flu, to the point where Billy Lemon can't even remember how many times he's had it.

13 Apr 2021

Africa's health systems are failing to meet the needs of vulnerable groups

Less than half the population of Africa are not receiving the health services they need, with vulnerable groups including gay and disabled people left behind, says a report.

31 Mar 2021

Mucosal delivery of IFNs a good strategy for COVID-19 prophylaxis post-exposure

Researchers from the UK and Germany recently reported a comprehensive characterization of the SARS-CoV-2 response of human nasal epithelial cells, revealing a response dominated by IFN-I/IIIs. Also, recombinant IFN-I/III treatment was found to efficiently block the replication of SARS-CoV-2, which suggests that mucosal delivery of IFNs may be a good strategy for prophylaxis post-exposure.

22 Feb 2021

Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection

Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.

10 Feb 2021

Researchers report trial results of rectal microbicides at HIV R4P Virtual Conference

Researchers seeking to develop on-demand and behaviorally congruent HIV prevention options for people who practice anal sex are reporting the results of three early phase clinical trials of rectal microbicides at this week's HIV Research for Prevention (HIV R4P) Virtual Conference.

3 Feb 2021

Study explores women's interest in long-acting injectable antiretroviral therapy

A study led by Columbia University Mailman School of Public Health researchers examines attitudes toward long-acting injectable (LAI) HIV therapies, among women with a history of injection--including medical purposes and substance use. The findings appear in the journal AIDS Patient Care and STDs.

7 Jan 2021

PrEP prescription can make a positive difference in women who inject drugs

When taken daily, pre-exposure prophylaxis, or PrEP, is a highly effective way to prevent HIV transmission, according to the Centers for Disease Control and Prevention.

16 Dec 2020

UofL receives DoD funding to develop a nasal spray for preventing COVID-19

The University of Louisville has received funding from the U.S. Department of Defense (DoD) to develop a nasal spray to prevent serious viral respiratory infections such as COVID-19 using Q-Griffithsin, a drug compound developed and co-owned by UofL.

9 Dec 2020

Chloroquine/hydroxychloroquine could treat COVID-19 infection

The recent serious outbreak of Covid19 has affected (November 13, 2020) 53,796,098 people worldwide, resulting in 37,555,669 recovered, 1,310,250 deaths, and a large number of open cases.

1 Dec 2020

HIV-related health services in Thailand during COVID-19 pandemic

Thailand's key population-led health services (KPLHS) are a hallmark of the success of the country's HIV response.

30 Nov 2020

Cabotegravir highly effective in preventing HIV among women

UNAIDS has been strongly encouraged by groundbreaking new study results showing that the antiretroviral medicine cabotegravir administered by an injection every two months – prevents HIV among women.

10 Nov 2020

Trial results show CAB LA is more effective in preventing HIV acquisition in women

The HIV Prevention Trials Network study (HPTN 084) on the safety and efficacy of the long-acting injectable antiretroviral drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women, was stopped early by the trial Data and Safety Monitoring Board (DSMB) as results showed CAB LA to be highly effective in preventing HIV acquisition.

10 Nov 2020

Hydroxychloroquine does not prevent COVID-19 in health care workers, trial shows

University of Minnesota Medical School physician researchers studied hydroxychloroquine as a treatment to prevent COVID-19 for those with high-risk for exposure to the virus - health care workers.

21 Oct 2020

Study explores women's interest in long-acting injectable PrEP to prevent HIV

Oral pre-exposure prophylaxis (PrEP) is a highly effective method of reducing risk for HIV, yet use of PrEP is uniformly low, especially among women.

22 Sep 2020

PrEP prescribing is not routine for many medical practitioners, study finds

Only about 54% of medical practitioners surveyed say they have prescribed pre-exposure prophylaxis, or PrEP, to HIV-vulnerable patients, according to a new study by a Vanderbilt University Medical Center investigator.

17 Sep 2020

State-level policies are crucial to HIV prevention efforts

HIV prevention remains a public health priority in the United States. Pre-exposure prophylaxis (PrEP) is a drug regimen recommended for individuals who have engaged in behaviors that place them at elevated risk for HIV.

9 Sep 2020

Researchers launch study to evaluate safety of HIV prevention methods in breastfeeding women

The development of safe and effective HIV prevention methods for cisgender women has long been a global health priority, yet research in women during pregnancy and breastfeeding, when they are most vulnerable to infection, has lagged years behind.

31 Aug 2020

Short-term PrEP use could be a successful way to prevent HIV spread in at-risk men on vacation

Men at particular risk for HIV are very likely to consistently take prevention medication during vacations when their odds of contracting the virus are higher, according to a new study led by scientists at the University of Pittsburgh Graduate School of Public Health, The Fenway Institute and Harvard University.

12 Aug 2020

Clinical trials of hydroxychloroquine in COVID-19 outpatients reported as safe

According to new research, the use of hydroxychloroquine among outpatients in clinical trials, without high-risk factors for cardiac arrhythmia, is safe.

27 Jul 2020